Amneal buys Actavis’ Australian generics business
Amneal Pharmaceuticals has completed its acquisition of Actavis’ Australian-based generic pharmaceuticals business. Financial terms of the deal were not disclosed.
Amneal Pharmaceuticals has completed its acquisition of Actavis’ Australian-based generic pharmaceuticals business. Financial terms of the deal were not disclosed.
Related: Actavis gains final FDA approval for generic Subutex
Both companies vowed to work expeditiously to complete the transaction without disrupting the distribution of Actavis’ products. Click here to read the announcement.
The agreement grants Amneal, based in Switzerland, the right to distribute Actavis-labeled products on a transitional basis.
Ireland-based Actavis completed a buyout of Botox-maker Allergan Inc. for $66 billion earlier this month. After it gains shareholder approval, Actavis will adopt the Allergan name.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
